Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

Summary

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Cohorts 1-8 receive ABBV-400 alone (monotherapy), cohort 9 receives ABBV-400 with a strong CYP3A3 inhibitor (ITZ), and cohort 10 receives ABBV-400 with bevacizumab.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Hepatocellular Carcinoma
• Pancreatic Ductal Adenocarcinoma
• Biliary Tract Cancers
• Esophageal Squamous Cell Carcinoma
• Triple Negative Breast Cancer
• Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
• Head and Neck Squamous-Cell Carcinoma
• Platinum Resistant High Grade Epithelial Ovarian Cancer

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

AbbVie

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites